rs2920502 — PPARG PPARG rs2920502

PPARG rs2920502 — An Intronic Risk Modifier for Body Fat and Glucose Metabolism

PPARG (Peroxisome Proliferator-Activated Receptor Gamma) is a nuclear transcription factor that sits at the heart of adipocyte biology. It controls how preadipocytes differentiate into fat cells, regulates fatty acid storage and oxidation, and determines how well tissues respond to insulin. PPARG is also the molecular target of thiazolidinedione¹¹ thiazolidinedione
A class of insulin-sensitizing diabetes drugs including pioglitazone and rosiglitazone that work by directly activating PPARG diabetes medications. The rs2920502 variant lies within intron 1 of the PPARG gene at chromosome 3p25.2 and has emerged from both large-scale GWAS and population-specific association studies as a functional modifier of adipogenesis and glucose homeostasis.

The Mechanism

rs2920502 is classified as an intronic regulatory variant sitting within a region of PPARG that has long-range regulatory activity²² long-range regulatory activity
The GWAS Catalog classifies rs2920502 as a regulatory_region_variant influencing PPARG expression, not a coding change. The C allele of rs2920502 is thought to alter the local chromatin environment or transcription factor binding within PPARG intron 1, subtly shifting the transcriptional output of the gene. This mechanistic model is consistent with the PPARG locus having multiple independent regulatory variants (rs1801282 Pro12Ala, rs1175543, rs17036314) spread across the gene that each contribute to the same downstream phenotype — adipocyte differentiation capacity and insulin sensitivity.

Because PPARG drives adipogenesis (fat cell formation), variants that modestly increase PPARG expression or alter its transcriptional activity can tip the balance toward greater fat accumulation — particularly visceral and ectopic fat — and impaired insulin signaling. The C allele at rs2920502 appears to carry this adipogenic risk.

The Evidence

A large genome-wide association study identified rs2920502 as a significant locus for body fat percentage³³ body fat percentage
Association ID 132681528, GWAS Catalog; beta = +0.19 units per C allele, SE = 0.02 with a p-value of 3.0 × 10⁻¹⁷ — a genome-wide significant signal reflecting a consistent, replicable association between the C allele and higher body fat.

At the genotype level, Zhou et al. 2018⁴⁴ Zhou et al. 2018
Zhou et al. Uncoupling Protein 2 and Peroxisome Proliferator-Activated Receptor γ Gene Polymorphisms in Association with Diabetes Susceptibility. Int J Endocrinol, 2018 studied 589 Chinese Han subjects and found that the GG genotype conferred decreased risk of impaired glucose tolerance (OR 0.715, 95% CI 0.527–0.97, p=0.031) and was associated with better blood glucose control, increased insulin secretion, and lower HOMA-IR compared to GC/CC carriers. This positions C allele carriers as having a meaningful disadvantage in glucose metabolism.

Song et al. 2017⁵⁵ Song et al. 2017
Song et al. Association of gene variants of transcription factors PPARγ, RUNX2, Osterix genes and COL2A1, IGFBP3 genes with osteonecrosis of the femoral head. Bone, 2017 found that the CC genotype was significantly associated with osteonecrosis of the femoral head across multiple inheritance models (co-dominant p=0.004; dominant p=0.013) and that CC genotype carriers had statistically elevated serum triglyceride levels (p=0.011). PPARG's role in lipid partitioning — directing fatty acids toward storage vs. oxidation — is a plausible mechanistic bridge between the variant and both ectopic lipid accumulation in bone marrow and circulating triglycerides.

Gene-environment interaction analyses have further identified rs2920502 as a participant in multi-locus models⁶⁶ multi-locus models
Qian et al. 2018 (PMID 29266977) and Zhu et al. 2019 (PMID 30793973) using MB-MDR analysis in 1,591 Chinese adults for both hypertension and nonalcoholic fatty liver disease (NAFLD) susceptibility when combined with angiotensin II receptor type 1 (AGTR1) variants. These interactions suggest that rs2920502's metabolic effects extend to blood pressure regulation and hepatic lipid accumulation — conditions downstream of impaired insulin sensitivity.

Practical Implications

The C allele at rs2920502 is most common in East Asian populations (~74% allele frequency) and South Asian populations (~64%), compared to ~31% in Europeans and only ~10% in African populations. Given these frequencies, CC homozygosity affects roughly 8% of the global population (and substantially more in East/South Asian ancestries).

The primary action areas mirror the known biology of impaired PPARG function: monitoring for early insulin resistance, managing body fat accumulation — particularly visceral fat — and tracking triglycerides and blood glucose over time. Because PPARG is the target of thiazolidinedione drugs (pioglitazone, rosiglitazone), clinicians managing type 2 diabetes in C allele carriers should be aware that variants in this locus can influence drug response.

Interactions

rs2920502 sits within the same PPARG locus as the well-studied Pro12Ala variant rs1801282⁷⁷ rs1801282
The best-characterized PPARG variant; Ala allele protective for T2D with OR 0.86 in 60-study meta-analysis. While they are in the same gene, they have independent functional consequences — rs1801282 is a coding missense in exon B while rs2920502 is intronic. Haplotype combinations of multiple PPARG variants likely have additive or compound effects on adipocyte differentiation capacity.

Gene-gene interaction studies consistently point to interactions between PPARG variants (including rs2920502) and AGTR1 (angiotensin II type 1 receptor) variants in determining metabolic syndrome, hypertension, and NAFLD risk — suggesting that PPARG's metabolic influence is amplified by renin-angiotensin system tone.